References

1. Allaoui-Attarki, K. et al. Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres. Infect Immun 65,853-7 (1997).
2. Allaoui-Attarki, K. et al. Mucosal immunogenicity elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly (D,L-Iactide-co-glycolide) microspheres. Vaccine 16, 685-91 (1998).
3. Alvarado, I.R.; Villegas, P.; El-Attrache, J.; Brown, T.P.   "Evaluation of the Protection Conferred by Commercial Vaccines Against the California 99 Isolate of Infectious Bronchitis Virus."   Avian Diseases .   2003, 47: 1298-1304.
4. Astell, Caroline, Steven Jones, and Marco Marra. "The Genome Sequence of the SARS-Associated Coronavirus." Science 300 (2003): 1399-1404. 2 Apr. 2004 <http://www.sciencemag.org/cgi/content/full/300/5624/1399>.
5. Aynaud, J.M. et al. Induction of lactogenic immunity to transmissible gastroenteritis virus of swine using an attenuated coronavirus mutant able to survive in the physicochemical environment of the digestive tract. Vet Microbio/26, 227-39 (1991).
6. Babcock, G., Thomas, W. & Hernandez, H. Expression and Immunogenicity of Recombinant SARS Spike Protein. in 41st ANNUAL MEETING OF IDSA, OCTOBER 9-12,2003 (San Diego, CA, 2003).
7. Baca-Estrada, M.E.; Babiuk, L.A.; Yoo, D.   "Hemaglutinin-Esterase Glycoprotein Gene of Bovine Coronavirus Delivered by Adenovirus Vector Induces Mucosal Immunity in Cotton Rats."   Mechanisms in the Pathogenesis of Enteric Disease.   Plenum Press, New York, 1997.
8. Ballesteros, M.L., Sanchez, C.M. & Enjuanes, L. Two amino acid changes at the N-terminus of transmissible gastroenteritis coronavirus spike protein result in the loss of enteric tropism. Virology 227, 378-88 (1997).
9. Barnfield, C. et al. The cellular basis of immune induction at mucosal surfaces by DNA vaccination. Oev BioI (Basel) 104, 159-64 (2000).
10. Beijing Group of National Research Project for SARS.  Dynamic changes in blood cytokine levels as clinical indicators in severe acute respiratory syndrome. Chin Med J (Engl). 2003 Sep;116(9):1283-7.
11. Berger, A., C. Drosten, H.W. Doerr, M. Stürmer, and W. Preiser. (2004). Severe acute respiratory syndrome (SARS)­--paradigm of an emerging viral infection. Journal of Clinical Virology. 29:13-22.
12. Bergmann CC, Dimacali E, Stohl S, Marten N, Lai MM, Stohlman SA. Viral evolution and CTL epitope stability during JHMV infection in the central nervous system. Adv Exp Med Biol 1998;440:751-7.
13. Brim TA, VanCott JL, Lunney JK, Saif LJ. Cellular immune responses of pigs after primary inoculation with porcine respiratory coronavirus or transmissible gastroenteritis virus and challenge with transmissible gastroenteritis virus. Vet Immunol Immunopathol 48(1-2):35-54.
14. Byron E. E. Martina, Bart L. Haagmans, Thijs Kuiken, Ron A. M. Fouchier, Guus F. Rimmelzwaan, Geert Van Amerongen, J. S. Malik Peiris, Wilina Lim & Albert D. M. E. Osterhaus  Virology: SARS virus infection of cats and ferrets Nature 425, 915 (30 October 2003);
15. Castro RF, Perlman S. CD8+ T-cell epitopes within the surface glycoprotein of a neurotropic coronavirus and correlation with pathogenicity. J Virol 1995;69(12):8127-31.
16. Cavanagh, D.   "Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus."   Avian Pathology.   Dec. 2003, V 32, No 6: 567-583.
17. Centers for Disease Control.   "Efficiency of Quarantine During an Epidemic of Severe Acute Respiratory Syndrome- Beijing, China, 2003.   Morbidity and Mortality Weekly Report.   Oct 31, 2003, V 52, No 43: 1037-1040.
18. Centers for Disease Control.   "Updated Interim Surveillance Case Definition for Severe Acute Respiratiory Syndrome (SARS)- United States, April 29, 2003."   Morbidity and Mortality Weekly Report.   2003, V 52, No 17: 391-393
19. Centers for Disease Control.   "Use of Quarantine to Prevent Transmission of Severe Acute Respiratory Syndrome- Taiwan 2003."   Morbidity and Mortality Weekly Report.   July 25, 2003, V 52 No 29: 680-683.
20. Chang, M.-S., Y.-T. Lu, S.-T. Ho, C.-C. Wu, T.-Y. Wei, C.-J. Chen, Y.-T. Hsu, P.-C. Chu, C.-H. Chen, J.-M. Chu, Y.-L. Jan, C.-C. Hung, C.-C. Fan, and Y.-C. Yang. (2004). Antibody detection of SARS-CoV spike and nucleocapsid protein. Biochemical and Biophysical Research Communications. 314:931-936.
21. Chan-Yeung, Moira, and Rui-Heng Xu. "SARS: epidemiology." Respirology 8 (2003):S9-S14. 2 Apr. 2004
22. Che, X.Y., W. Hao, L.W. Qiu, Y.X. Pan, Z.Y. Liao, H. Xu, J.J. Chen, J.L. Hou, P.C. Woo, S.K. Lau, Y.Y. Kwok, and Z. Huang. (2003). [Antibody response of patients with severe acute respiratory syndrome (SARS) to nucleocapsid antigen of SARS-associated coronavirus]. Di Yi Jun Yi Da Xue Xue Bao. 7:637-639.
23. Chen, H.; Schifferli, D.M. "Enhanced immune responses to viral epitopes by combining macrophage-inducible expression with multimeric display on a Salmonella vector." Vaccine . (2001) 19: 3009-3018
24. Chen, Z., D. Pei, L. Jiang, Y. Song, J. Wang, H. Wang, D. Zhou, J. Zhai, Z. Du, B. Li, M. Qiu, Y. Han, Z. Guo, and R. Yang. (2004). Antigenicity Analysis of Different Regions of the Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Protein. Clinical Chemistry. 50:article in press.
25. Childers, N.K., et al., A controlled clinical study of the effect of nasal immunization with a Streptococcus mutans antigen alone or incorporated into liposomes on induction of immune responses. Infect Immun, 1999. 67 (2): p. 618-23.
26. Chua MM, Phillips JJ, Seo SH, Lavi E, Weiss SR. Mutation of the immunodominant CD8+ epitope in the MHV-4 spike protein. Adv Exp Med Biol 2001;494:121-5.
27. Collisson, EW., Pei, J., Dzielawa, J. & Seo, S.H. Cytotoxic T lymphocytes are critical in the control of infectious bronchitis virus in poultry. Oev Comp Immuno/24, 187-200 (2000).
28. Consensus document on the epidemiology of severe acute respiratory syndrome (SARS). 23 May 2003. World Health Organization: Department of Communicable Disease Surveillance and Response. 2 Apr. 2004
29. Corapi, W.V.; Darteil, R.J.; Audonnet, J.C.; Chappuis, G.E. "Localization of Antigenic Sites of the S Glycoprotein of Feline Infectious Peritonitis Virus Involved in Neutralization and Antibody-Dependent Enhancement." Journal of Virology . May 1995, 69 (5): p. 2858-2862.
30. Crouch, C.F.; Oliver, S.; Hearle, D.C.; Buckley, A.; Chapman, A.J.; Francis, M.J.   "Lactogenic immunity following vaccination of cattle with bovine coronavirus."   Vaccine.   2001, 19: 189-196.
31. Das Sarma, J., Fu, L., Hingley, ST., Lai, M.M. & Lavi, E. Sequence analysis of the S gene of recombinant MHV-2/A59 coronaviruses reveals three candidate mutations associated with demyelination and hepatitis. J Neurovirol7, 432-6 (2001).
32. de Arriba ML, Carvajal A, Pozo J, Rubio P. Lymphoproliferative responses and protection in conventional piglets inoculated orally with virulent or attenuated porcine epidemic diarrhoea virus. J Virol Methods 2002;105(1):37-47.
33. De Groot, A.S. (2003). How the SARS vaccine effort can learn from HIV­­--speeding towards the future, learning from the past. Vaccine. 21:4095-4104.
34. de Haan, C.A., Masters, P.S., Shen, X., Weiss, S. & Rottier, P.J. The group-specific murine coronavirus genes are not essential, but their deletion, by reverse genetics, is attenuating in the natural host. Virology 296, 177-89 (2002).
35. Denis-Mize, K.S. et al. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther7, 2105-12 (2000).
36. Drosten, C., W. Preiser, S. Günther, H. Schmitz, and H.W. Doerr. (2003). Severe acute respiratory syndrome: identification of the etiological agent. Trends in Molecular Medicine. 9:325-327.
37. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348(20):1967-76.
38. Enserink, M. Infectious diseases. Searching for a SARS agenda. Science 300, 1487-8 (2003).
39. Eriksson, K. & Holmgren, J. Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol 14,666-72 (2002).
40. Farsang A, Ros C, Renstrom LH, Baule C, Soos T, Belak S. Molecular epizootiology of infectious bronchitis virus in Sweden indicating the involvement of a vaccine strain. Avian Pathol 2002;31(3):229-36.
41. Falero-Diaz, G., et al., Intranasal vaccination of mice against infection with Mycobacterium tuberculosis. Vaccine, 2000. 18 (28): p. 3223-9.
42. Fouchier, R.A.M., T. Kuiken, M. Schutten, G. van Amerongen, G.J.J. van Doornum, B.G. van den Hoogen, M. Peiris, W. Lim, K. Stöhr, and A.D.M.E. Osterhaus. (2003). Aetiology: Koch's postulates fulfilled for SARS virus. Nature. 423:240.
43. Gao, W., A. Tamin, A. Soloff, L. D'Aiuto, E. Nwanegbo, P.D. Robbins, W.J. Bellini, S. Barratt-Boyes, A. Gambotto. (2003). Effects of a SARS-associated coronavirus in monkeys. The Lancet. 362:1895-1896.
44. Greaves, MW.   "Coping with SARS: A day in the life of a United Kingdom dermatologist in Singapore General Hospital."   Journal of the American Academy of Dermatology.   2004, 50: E2-E5.
45. Guan, Y. et al. Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China. Science (2003).
46. Hasoksuz M, Sreevatsan S, Cho KO, Hoet AE, Saif LJ. Molecular analysis of the S1 subunit of the spike glycoprotein of respiratory and enteric bovine coronavirus isolates. Virus Res 2002;84(1-2):101-9. 48(1-2):35-54.
47. Hao, X.; Zhang, J.; Guo, Y.   "Study of new protective clothing against SARS using semi-permeable PTFE/PU membrane."   European Polymer Journal.   2004.
48. He, L., Y.Q. Ding, X.Y. Che, Q.L. Zhang, Z.X. Huang, H.J. Wang, H. Shen, Z.G. Li, J.J. Cai, J.H. Zhang, J. Geng, X. Li, W.L. Zhang, H.X. Han, W. Kang, L. Yang, and Y.D. Lu. (2003). [Expression of the monoclonal antibody against nucleocapsid antigen of SARS-associated coronavirus in autopsy tissues from SARS patients]. Di Yi Jun Yi Da Xue Xue Bao. 11:1128-1130.
49. He, R., A. Leeson, A. Andonov, Y. Li, N. Bastien, J. Cao, C. Osiowy, F. Dobie, T. Cutts, M. Ballantine, and X. Li. (2003). Activation of AP-1 signal transduction pathway by SARS coronavirus nucleocapsid protein. Biochemical and Biophysical Research Communications. 311:870-876.
50. He, R., F. Dobie, M. Ballantine, A. Leeson, Y. Li, N. Bastien, T. Cutts, A. Andonov, J. Cao, T.F. Booth, F.A. Plummer, S. Tyler, L. Baker, and X. Li. (2004). Analysis of multimerization of the SARS coronavirus nucleocapsid protein. Biochemical and Biophysical Research Communications. 316:476-483.
51. He L, Ding YQ, Wang W, Zhang QL, Zhang JH, Geng J, Cai JJ. Expression of immune cells and their roles in the involved tissues of SARS patients. Di Yi Jun Yi Da Xue Xue Bao. 2003 Aug;23(8):774-6, 780.
52. Herrewegh, A.A., Smeenk, I., Horzinek, M.C., Rottier, P.J. & de Groot, R.J. Feline coronavirus type II strains 79-1683 and 79-1146 originate from a double recombination between feline coronavirus type I and canine coronavirus. J Virol72, 4508-14 (1998).
53. Ho, P.L.; Tang, X.P.; Seto, W.H.   "SARS: hospital infection control and admission strategies."   Respirology.   2003, 8: S41-S45.
54. Ho, T.-Y., S.-L. Wu, S.-E. Cheng, Y.-C. Wei, S.-P. Huang, and C.-Y. Hsiang. (2004). Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein. Biochemical and Biophysical Research Communications. 313:938-947.
55. Holmes, KV. SARS coronavirus: a new challenge for prevention and therapy. J Clin Invest 111, 1605-9 (2003).
56. Hui, D.S.C.; Wong, P.C.; Wang, C.   "SARS, clinical features and diagnosis."   Respirology.   2003, 8: S20-S24.
57. Ignjatovic, J. & Galli, L. The S1 glycoprotein but not the N or M proteins of avian infectious bronchitis virus induces protection in vaccinated chickens. Arch Viro/138, 117-34 (1994).
58. Interim Domestic Guidance on the Use of Respirators to Prevent Transmission of SARS. 6 May 2003. Center for Disease Control. 6 Apr. 2004 <http://www.cdc.gov/ncidod/sars/respirators.htm>.
59. J. Cinatl, B. Morgenstern, G. Bauer, P. Chandra, H. Rabenau and H.W. Doerr, Treatment of SARS with human interferons. Lancet 362 (2003), pp. 293-294.
60. Johnson, M.A., Pooley, C., Ignjatovic, J. & Tyack, S.G. A recombinant fowl adenovirus expressing the S 1 gene of infectious bronchitis virus protects against challenge with infectious bronchitis virus. Vaccine 21, 2730-6 (2003).
61. Kaneko, H. et al. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. Virology 267,8-16 (2000).
62. Kapczynski, D.R.; Hilt, D.A.; Shapiro, D.; Sellers, H.; Jackwood, M.W.   "Protection of Chickens from Infectious Bronchitis by In Ovo and Intramuscular Vaccinations with a DNA Vaccine Expressing the S1 Glycoprotein."   Avian Diseases.   2003, 47: 272-285.
63. Keck, J.G. et al. In vivo RNA-RNA recombination of coronavirus in mouse brain. J Viro/62, 1810-3 (1988).
64. Kidd, M.T., Peebles, E.D., Whitmarsh, S.K., Yeatman, J.B. & Wideman, R.F., Jr. Growth and immunity of broiler chicks as affected by dietary arginine. Poult Sci 80, 1535-42 (2001).
65. Koden MJ, Borst MA, Horsinek MC, Spaan WJ. Immunogenic peptide comprising a mouse hepatitis virus A59 B-cell epitope and an influenza virus T-cell epitope protects against lethal infection. J Virol 1990;64(12):6270-3.
66. Koletzki, D. et al. Mosaic hepatitis B virus core particles allow insertion of extended foreign protein segments. J Gen Viro178, 2049-53. (1997).
67. Koolen, M.J.M., M.A.J. Borst, M.C. Horzinek, and W.J.M. Spaan. (1990). Immunogenic Peptide Comprising a Mouse Hepatitis Virus A59 B-Cell Epitope and an Influenza Virus T-Cell Epitope Protects against Lethal Infection. Journal of Virology. 64:6270-6273.
68. Ksiazek, Thomas G. Finding SARS: The Identification of a New Coronavirus during an International Outbreak . Centers for Disease Control and Prevention. New York Academy
    of Sciences, NY. 19 Nov. 2003. 2 Apr. 2003 <http://members
    .nyas.org/epups/emin/03_1218.html>.
69. La Montagne JR, Simonsen L, Taylor RJ, Turnbull J; SARS Research Working Group Co-Chairs. Severe acute respiratory syndrome: developing a research response. J Infect Dis. 2004 Feb 15;189(4):634-41
70. Lam, W.K.; Zhong, N.S.; Tan, W.C.   "Overview of SARS in Asia and the World."   Respirology.   2003, 8: S2-S5.
71. Lanconescu, M., Smith, E.J., Fadly, A.M. & Nazerian, K. An enzyme-linked immunosorbent assay for detection of hemorrhagic enteritis virus and associated antibodies. Avian Ois 28,677-92 (1984).
72. Lechner, F. et al. Virus-like particles as a modular system for novel vaccines. Intervirology 45, 212-7 (2002).
73. Leung, T.F.; Ng, P.C.; Cheng, F.W.T.; Lyon, D.J.; So, K.W.; et al.   "Infection control for SARS in a tertiary pediatric centre in Hong Kong."   Journal of Hospital Infection.   2004, 56: 215-222.
74. Lhou, X.l. et al. [Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute respiratory syndrome in Beijing area]. Zhonghua Yi Xue Za Zhi 83, 1018-22 (2003).
75. Li Z, Guo X, Hao W, Wu Y, Ji Y, Zhao Y, Liu F, Xie X. The relationship between serum interleukins and T-lymphocyte subsets in patients with severe acute respiratory syndrome. Chin Med J (Engl). 2003 Jul;116(7):981-4.
76. Liò, P. and N. Goldman. (2004). Phylogenomics and bioinformatics of SARS-CoV. Trends in Microbiology. 12:106-111.
77. Liu, C.; Kokuho, T.; Kubota, T.; Watanabe, S.; Inumaru, S.; Yokomizo, Y.; Onodera, T.   "DNA mediated immunization with encoding the nucleoprotein gene of porcine transmisible gastroenteritis virus."   Virus Research.   2001, 80: 75-82.
78. Liu, C., T. Kokuho, T. Kubota, S. Watanabe, S. Inumaru, Y. Yokomizo, and T. Onodera. (2001). DNA mediated immunization with encoding the nucleoprotein gene of porcine transmissible gastroenteritis virus. Virus Research. 80:75-82.
79. Liu MF, Ning Q, Pope M, et al. Resistance of naive mice to murine hepatitis virus strain 3 requires development of a Th1, but not a Th2, response, whereas pre-existing antibody partially protects against primary infection. Adv Exp Med Biol 1998;440:415-23.
80. Liu, S., G. Xiao, Y. Chen, Y. He, J. Niu, C.R. Escalante, H. Xiong, J. Farmar, A.K. Debnath, P. Tien, and S. Jiang. (2004). Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. The Lancet. 363:938-947.
81. Liu, X., Y. Shi, P. Li, L. Li, Y. Yi, Q. Ma, and C. Cao. (2004). Profile of Antibodies to the Nucleocapsid Protein of the Severe Acute Respiratory Syndrome (SARS)-Associated Coronavirus in Probable SARS Patients. Clinical and Diagnostic Laboratory Immunology. 11:227-228.
82. Loa CC, Lin TL, Wu CC, et al. Humoral and cellular immune responses in turkey poults infected with turkey coronavirus 2001;80(10):1416-24.
83. Lund, O. et al. T-cell Epitopes Useful in a Severe Acute Respiratory Syndrome (SARS) Virus Vaccine and as Diagnostic Tools and Methods for Identifying Same. (DTU, Denmark, 2003).
84. Makino, S., Keck, J.G., Stohlman, S.A. & Lai, M.M. High-frequency RNA recombination of murine coronaviruses. J Viro157, 729-37 (1986).
85. Marra, M.A. et al. The Genome sequence of the SARS-associated coronavirus. Science 300, 1399­404. (2003).
86. McGoldrick, A., Lowings, J.P. & Paton, D.J. Characterisation of a recent virulent transmissible gastroenteritis virus from Britain with a deleted ORF 3a. Arch Viro/144, 763-70 (1999).
87. Merlat, Annabelle, et al. "Coronavirus 229E Related Pneumonia in Immunocompromised Patients." Clinical Infectious Diseases 37 (2003): 929-932. 1 Apr. 2004.
88. Naqi, S.; Gay, K.; Patalla, P.; Mondal, S.; Liu, R.   "Establishment of Persistent Avian Infectious Bronchitis Infection in Antibody-Free and Antibody-Positive Chickens."   Avian Diseases.   2003, 47: 594-601.
89. Nicholls JM, Poon LL, Lee KC. Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003;361(9371):1773-8.
90. O'Connor A, Martin SW, Nagy E, Menzies P, Harland R. The relationship between the occurrence of undifferentiated bovine respiratory disease and titer changes to bovine coronavirus and bovine viral diarrhea virus in 3 Ontario feedlots. Can J Vet Res 2001;65(3):137-42.
91. Ontiveros, E, Kim, TS., Gallagher, TM. & Perlman, S. Enhanced virulence mediated by the murine coronavirus, mouse hepatitis virus strain JHM, is associated with a glycine at residue 310 of the spike glycoprotein. J Virol77, 10260-9 (2003).
92. Pang, X.; Zhu, Z.; Xu, F.; Guo, J.; Gong, X.; Liu, D.; Liu, Z.; Chin, D.P.; Feikin, D.R.   "Evaluation of Control Measures Implemented in the Severe Acute Respiratory Syndrome Outbreak in Beijing, 2003."   Journal of the American Medical Association.   Dec 24/31, 2003, V 290, No. 24: 3215, 3221.
93. Park, S. et al. Immune response of sows vaccinated with attenuated transmissible gastroenteritis virus (TGEV) and recombinant TGEV spike protein vaccines and protection of their suckling pigs against virulent TGEV challenge exposure. Am J Vet Res 59, 1002-8 (1998).
94. Pei, J., Briles, W.E & Collisson, E.W. Memory T cells protect chicks from acute infectious bronchitis virus infection. Virology 306, 376-84 (2003).
95. Peiris, J.S. et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361, 1319-25. (2003).
96. Pensaert, M., Callebaut, P. & Vergote, J. Isolation of a porcine respiratory, non-enteric coronavirus related to transmissible gastroenteritis. Vet Q 8, 257-61 (1986).
97. Pewe L, Heard SB, Bergmann C, Dailey MO, Perlman S. Selection of CTL escape mutants in mice infected with a neurotropic coronavirus: quantitative estimate of TCR diversity in the infected central nervous system. J Immunol 1999;163(11):6106-13.
98. Pope M, Chung SW, Mosmann T, Leibowitz JL, Gorczynski RM, Levy GA. Resistance of naive mice to murine hepatitis virus strain 3 requires development of a Th1, but not a Th2, response, whereas pre-existing antibody partially protects against primary infection. J Immunol 1996;156(9):3342-9.
99. Prabakaran, P., X. Xiao, and D.S. Dimitrov. (2004). A model of the ACE2 structure and function as a SARS-CoV receptor. Biochemical and Biophysical Research Communications . 314:235-241.
100. Pratelli A, Tinelli A, Decaro N, et al. Efficacy of an inactivated canine coronavirus vaccine in pups. New Microbiol 2003;26(2):151-5.
101. Pumpens, P. & Grens, E HBV core particles as a carrier for B celllT cell epitopes. Intervirology 44,98­114 (2001).
102. Ratanasethakul, C. & Cumming, RB. Immune response of chickens to various routes of administration of Australian infectious bronchitis vaccine. Aust Vet J 60,214-6 (1983).
103. Register, K.B. & Wesley, RD. Molecular characterization of attenuated vaccine strains of transmissible gastroenteritis virus. J Vet Oiagn Invest 6, 16-22 (1994).
104. Reyes-Sandoval, A. & Ertl, HC. DNA vaccines. Curr Mol Med 1,217-43 (2001).
105. Rota, P.A., M.S. Oberste, S.S. Monroe, W.A. Nix, R. Campagnoli, J.P. Icenogle, S. Peñaranda, B. Bankamp, K. Maher, M.-H. Chen, S. Tong, A. Tamin, L. Lowe, M. Frace, J.L. DeRisi, Q. Chen, D. Wang, D.D. Erdman, T.C.T. Peret, C. Burns, T.G. Ksiazek, P.E. Rollin, A. Sanchez, S. Liffick, B. Holloway, J. Limor, K. McCaustland, M. Olsen-Rasmussen, R. Fouchier, S. Günther, A.D.M.E. Osterhaus, C. Drosten, M.A. Pallansch, L.J. Anderson, and W.J. Bellini. (2003). Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome. Science. 300:1394-1399.
106. Ruan Y, Wei CL, Ee AL, et al. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet 2003;361:1779-85.
107. Rudin, A., et al., Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. Infect Immun, 1998. 66 (7): p. 3390-6.
108. Ruan Y, Wei CL, Ee AL, et al. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet 2003;361:1779-85.
109. Rudin, A., et al., Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. Infect Immun, 1998. 66 (7): p. 3390-6.
110. Seo, S.H., Wang, L., Smith, R & Collisson, EW. The carboxyl-terminal 120-residue polypeptide of infectious bronchitis virus nucleocapsid induces cytotoxic T lymphocytes and protects chickens from acute infection. J Viro171, 7889-94 (1997).
111. Sette, A. & Sidney, J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50,201-12 (1999)
112. Severe acute respiratory syndrome. 28 May 2003. World Health Assembly. 7 Apr. 2004 <http://www.who.int/gb/EB_WHA/PDF/WHA56/ea56r29.pdf>.
113. Sharma, A.K. & Khuller, G.K. DNA vaccines: future strategies and relevance to intracellular pathogens. Immunol Cell BioI 79, 537-46 (2001).
114. Subbarao, K. et al. Prior infection and passive transfer of neutralizing antibody prevent replication of SARS coronavirus in the respiratory tract of mice. J. Virol. 78, 3572-3577 (2004) 
115. Sui, J., W. Li, A. Murakami, A. Tamin, L.J. Matthews, S.K. Wong, M.J. Moore, A.St.C. Tallarico, M. Olurinde, H. Choe, L.J. Anderson, W.J. Bellini, M. Farzan, and W.A. Marasco. (2004). Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proceedings of the National Academy of Sciences of the United States of America. 101:2536-2541.
116. Sun, H., H. Luo, C. Yu, T. Sun, J. Chen, S. Peng, J. Qin, J. Shen, Y. Yang, Y. Xie, K. Chen, Y. Wang, X. Shen, and H. Jiang. (2003). Molecular cloning, expression, purification, and mass spectrometric characterization of 3C-like protease of SARS coronavirus. Protein Expression and Purification. 32:302-308.
117. Wang, P., J. Chen, A. Zheng, Y. Nie, X. Shi, W. Wang, G. Wang, M. Luo, M. Liu, L. Tan, X. Song, Z. Wang, X. Yin, X. Qu, X. Wang, T. Qing, M. Ding, and H. Deng. (2004). Expression cloning of functional receptor used by SARS coronavirus. Biochemical and Biophysical Research Communications. 315:439-444.
118. Takamura K, Matsumoto Y, Shimizu Y. Field study of bovine coronavirus vaccine enriched with hemagglutinating antigen for winter dysentery in dairy cows. Can J Vet Res 2002;66(4):278-81.
119. Tan, Y.-J., P.-Y. Goh, B.C. Fielding, S. Shen, C.-F. Chou, J.-L. fu, H.N. Leong, Y.S. Leo, E.E. Ooi, A.E. Ling, S.G. Lim, and W. Hong. (2004). Profiles of Antibody Responses against Severe Acute Respiratory Syndrome Coronavirus Recombinant Proteins and Their Potential Use as Diagnostic Markers. Clinical and Diagnostic Laboratory Immunology. 11:362-371.
120. Thomson, S.A. et al. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J Immuno/157, 822-6 (1996).
121. Thomson SA, et al. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. J Immunol. 160(4): 1717-1723.
122. Thomson SA, et al. Minimal epitopes expressed in a recombinant 'polyepitope' protein are processed and presented to CD8 cytotoxic T cells: implications for polyepitope vaccine design. Proc Natl Acad Sci U S A . 92: 5845-5849.
123. Timani, K.A., L. Ye, L. Ye, Y. Zhu, Z. Wu, Z. Gong. (2004). Cloning, sequencing, expression, and purification of SARS-associated coronavirus nucleocapsid protein for serodiagnosis of SARS. Journal of Clinical Virology. Article in press.
124. Tobler, K., Ackermann, M. & Griot, C. [SARS, possible zoonosis in the area of conflict of pathogenic coronaviruses of animals]. Schweiz Arch Tierheilkd 145,316-22 (2003).
125. van der Hoek, Lia. "Identification of a new human coronavirus." Nature Medicine 10 (2004): 368-373. 2 Apr. 2004 <http://www.nature.com/cgi-taf/DynaPage.taf?file=/nm/journal/v10/n4/abs/nm1024.html&dynoptions=doi1081486379>.
126. Vennema, H. et al. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J Viro164, 1407-9 (1990).
127. Wang, X.; Schnitzlen, W.M.; Tripathy, D.N.; Girshick, T.; Khan, M.I.   "Construction and Immunogenicity Studies of Recombinant Fowl Poxvirus Containing the S1 Gene of Massachusetts 41 Strain of Infectious Bronchitis Virus."   Avian Disease.   2002, 46: 831-838.
128. Weiss, RC. & Scott, F.W. Pathogenesis of feline infetious peritonitis: pathologic changes and immunofluorescence. Am J Vet Res 42,2036-48 (1981).
129. Welter, M.   "Adaptation and Serial Passage of Bovine Coronaviruses in an Established Diploid Swine Testicular Cell Line and Subsequent Development of a Modified Live Vaccine."   Advances in Experimental Medical Biology.   1998, 440: 707-711.
130. Wierzbicki, A. et al. Immunization strategies to augment oral vaccination with DNA and viral vectors expressing HIV envelope glycoprotein. Vaccine 20, 1295-307 (2002).
131. Wong, V.W., Dai, D., Wu, A.K. & Sung, J.J. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J 9, 199-201 (2003).
132. Wu GF, Dandekar AA, Pewe L, Perlman S. CD4 and CD8 T cells have redundant but not identical roles in virus-induced demyelination. J Immunol 2000;165(4):2278-86.
133. Xue S, Perlman S. Antigen specificity of CD4 T cell response in the central nervous system of mice infected with mouse hepatitis virus. Virology 1997;238(1):68-78.
134. Yam, L.Y.C.; Chen, R.C.; Zhong, N.S.   "SARS: ventilatory and intensive care."   Respirology.   2003, 8: S31-S35 .
135. Yang, Z.-Y., W.-P. Kong, Y. Huang, A. Roberts, B.R. Murphy, K. Subbarao, and G.J. Navel. (2004). A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature. 428:561-564.
136. Zeng, F., K.Y.C. Chow, C.C. Hon, K.M. Law, C.W. Yip, K.H. Chan, J.S.M. Peiris, and F.C.C. Leung. (2004). Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments. Biochemical and Biophysical Research Communications. 315:1134-1139.
137. Zhang R, Guo Z, Lu J, Meng J, Zhou C, Zhan X, Huang B, Yu X, Huang M, Pan X, Ling W, Chen X, Wan Z, Zheng H, Yan X, Wang Y, Ran Y, Liu X, Ma J, Wang C, Zhang B.Inhibiting severe acute respiratory syndrome-associated coronavirus by small interfering RNA.Chin Med J (Engl). 2003 Aug;116(8):1262-4
138. Zhang, X.W. and Y.L. Yap. (2004). Exploring the binding mechanism of the main proteinase in SARS-associated coronavirus and its implication to anti-SARS drug design. Bioorganic & Medicinal Chemistry. 12:article in press.
139. Zhang, X.W. and Y.L. Yap. (2004). Structural similarity between HIV-1 gp41 and SARS-CoV S2 proteins suggests an analogous membrane fusion mechanism. Journal of Molecular Structure (Theochem). Article in press.
140. Zhao, P., J.-S. Ke, Z.-L. Qin, H. Ren, L.-J. Zhao, J.-G. Yu, J. Gao, S.-Y. Zhu, and Z.-T. Qi. (2004). DNA Vaccine of SARS-CoV S Gene Induces Antibody Response in Mice. Acta Biochim et Biophysica Sinica. 36:37-41.
141. Zhu, M.-S., Y. Pan, H.-Q. Chen, Y. Shen, X.-C. Wang, Y.-J. Sun, and K.-H. Tao. (2004). Induction of SARS-nucleoprotein-specific immune response by use of a DNA vaccine. Immunology Letters. Article in press.